Anti-HVEM and anti-BTLA monoclonal antibodies (mAbs) are currently undergoing clinical trials for the treatment of both cancer and autoimmune diseases. Despite their exceptionally high efficacy, mAbs also present certain drawbacks, the most significant being the high cost associated with their development and production, as well as immune-related adverse events (irAEs). Here, TNFRSF14 is linked to cancer.